Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/SN/A
P/E—
Fwd P/E13.52
PEG12.11
52W— – —
RSI—
Target$135.19 (+3.7%)
Beta0.20
Div2.49%
Loading chart…
RSI (14)
Loading patterns…
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 59
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
4Bullish
1Bearish
0Neutral
▲ Double Bottom — Two lows ~$108.64 — bullish reversal confirmed
▲ Inv. Head & Shoulders — Inv. H&S neckline ~$118.45 broken — major bullish reversal
▲ Bull Flag — Breakout after +9% pole — bullish continuation
▲ Double Bottom — Two lows ~$111.84 — bullish reversal confirmed
▼ Bear Flag — Breakdown after -9% pole — bearish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$135.19
+3.7% upside
Low $105
—
High $155
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | — | ↔ Maintain | 2026-07-29 |
| JP Morgan | Overweight | — | ↔ Maintain | 2026-07-13 |
| BMO Capital | Outperform | — | ↔ Maintain | 2026-07-13 |
| Guggenheim | Buy | — | ↔ Maintain | 2026-07-13 |
| Morgan Stanley | Equal-Weight | — | ↔ Maintain | 2026-07-09 |
| RBC Capital | Outperform | — | ↔ Reiterate | 2026-07-08 |
| Wells Fargo | Overweight | — | ↔ Maintain | 2026-07-08 |
| Cantor Fitzgerald | Neutral | — | ↔ Reiterate | 2026-07-06 |
| B of A Securities | Buy | — | ↔ Maintain | 2026-06-30 |
| Scotiabank | Sector Outperform | — | ↔ Maintain | 2026-06-30 |
| CICC | Outperform | — | ● Initiate | 2026-06-24 |
| UBS | Buy | — | ↔ Maintain | 2026-04-13 |
| Citigroup | Neutral | — | ↔ Maintain | 2026-03-20 |
| Freedom Broker | Hold | — | ↔ Maintain | 2026-02-09 |
| TD Cowen | Hold | — | ↔ Maintain | 2026-01-20 |
| Wolfe Research | Outperform | Peer Perform → Outperform | ▲ Upgrade | 2026-01-08 |
| Goldman Sachs | Buy | — | ↔ Maintain | 2025-12-02 |
| Deutsche Bank | Hold | — | ↔ Maintain | 2025-11-18 |
Barclays
2026-07-29
Overweight
↔ Maintain
JP Morgan
2026-07-13
Overweight
↔ Maintain
BMO Capital
2026-07-13
Outperform
↔ Maintain
Guggenheim
2026-07-13
Buy
↔ Maintain
Morgan Stanley
2026-07-09
Equal-Weight
↔ Maintain
RBC Capital
2026-07-08
Outperform
↔ Reiterate
Wells Fargo
2026-07-08
Overweight
↔ Maintain
Cantor Fitzgerald
2026-07-06
Neutral
↔ Reiterate
B of A Securities
2026-06-30
Buy
↔ Maintain
Scotiabank
2026-06-30
Sector Outperform
↔ Maintain
CICC
2026-06-24
Outperform
● Initiate
UBS
2026-04-13
Buy
↔ Maintain
Citigroup
2026-03-20
Neutral
↔ Maintain
Freedom Broker
2026-02-09
Hold
↔ Maintain
TD Cowen
2026-01-20
Hold
↔ Maintain
Wolfe Research
2026-01-08
Outperform
(from Peer Perform)
▲ Upgrade
Goldman Sachs
2025-12-02
Buy
↔ Maintain
Deutsche Bank
2025-11-18
Hold
↔ Maintain
Profitability
Gross Margin
76.73%TTM
Op. Margin
38.60%TTM
ROE
18.94%TTM
Rev. Growth
4.90%YoY
Free Cash Flow
14.05BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
106.94MRQ
Current Ratio
1.30MRQ
Cash
5.70BMRQ
Total Debt
49.12BMRQ
Net Debt
—MRQ
Income
Div. Yield
2.49%TTM
Annual Rate
3.40Fwd
Payout Ratio
93.52%TTM
Dividend History
Payout Ratio (TTM): 93.52%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-06-15 | $0.8500 | 0.74% |
| 2026-03-16 | $0.8500 | 0.74% |
| 2025-12-15 | $0.8500 | 0.86% |
| 2025-09-15 | $0.8100 | 1.02% |
| 2025-06-16 | $0.8100 | 1.03% |
| 2025-03-17 | $0.8100 | 0.89% |
| 2024-12-16 | $0.8100 | 0.85% |
| 2024-09-16 | $0.7700 | 0.69% |
| 2024-06-17 | $0.7700 | 0.65% |
| 2024-03-14 | $0.7700 | 0.69% |
| 2023-12-14 | $0.7700 | 0.79% |
| 2023-09-14 | $0.7300 | 0.73% |
| 2023-06-14 | $0.7300 | 0.74% |
| 2023-03-14 | $0.7300 | 0.75% |
| 2022-12-14 | $0.7300 | 0.73% |
| 2022-09-14 | $0.6900 | 0.89% |
| 2022-06-14 | $0.6900 | 0.92% |
| 2022-03-14 | $0.6900 | 1.01% |
| 2021-12-14 | $0.6900 | 1.07% |
| 2021-09-14 | $0.6500 | 1.04% |
| 2021-06-14 | $0.6500 | 1.01% |
| 2021-03-12 | $0.6202 | 1.03% |
| 2020-12-14 | $0.6202 | 0.96% |
| 2020-09-14 | $0.5821 | 0.87% |
| 2020-06-12 | $0.5821 | 0.96% |
| 2020-03-13 | $0.5821 | 0.97% |
| 2019-12-13 | $0.5821 | 0.84% |
| 2019-09-13 | $0.5248 | 0.82% |
| 2019-06-14 | $0.5248 | 0.83% |
| 2019-03-14 | $0.5248 | 0.84% |
| 2018-12-14 | $0.5248 | 0.91% |
| 2018-09-14 | $0.4580 | 0.87% |
| 2018-06-14 | $0.4580 | 1.00% |
| 2018-03-14 | $0.4580 | 1.13% |
| 2017-12-14 | $0.4580 | 1.11% |
| 2017-09-14 | $0.4485 | 0.93% |
| 2017-06-13 | $0.4485 | 0.98% |
| 2017-03-13 | $0.4485 | 0.97% |
| 2016-12-13 | $0.4485 | 1.02% |
| 2016-09-13 | $0.4389 | 1.00% |
How MRK Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | N/A |
| Enterprise Value | 365.43B |
| Trailing P/E | 36.72 |
| Forward P/E | 13.52 |
| PEG Ratio (5yr) | 12.11 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 7.02 |
| EV/Revenue | 5.56 |
| EV/EBITDA | 12.38 |
Share Statistics
| Avg Vol (3m) | 10.25M |
| Shares Outstanding | N/A |
| Float | 2.47B |
| % Held by Insiders | 0.06% |
| % Held by Institutions | 82.26% |
| Short Ratio | 2.59 |
| Short % of Float | 1.19% |
Profitability
| Gross Margin | 76.73% |
| Operating Margin (ttm) | 38.60% |
| Profit Margin | 13.59% |
| Return on Assets (ttm) | 12.58% |
| Return on Equity (ttm) | 18.94% |
Income Statement
| Revenue (ttm) | 65.77B |
| Revenue Growth (yoy) | 4.90% |
| Gross Profit (ttm) | 50.46B |
| EBITDA | 29.52B |
| Net Income (ttm) | 8.94B |
| Diluted EPS (ttm) | 3.55 |
| EPS Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.70B |
| Total Debt (mrq) | 49.12B |
| Debt / Equity (mrq) | 106.94 |
| Current Ratio (mrq) | 1.30 |
| Book Value / Share | 18.58 |
| Operating CF (ttm) | 17.89B |
| Free Cash Flow (ttm) | 14.05B |
Trading & Dividends
| Beta (5Y) | 0.20 |
| 50-Day MA | 122.19 |
| 200-Day MA | 111.15 |
| Fwd Dividend Yield | 258.00% |
| Payout Ratio | 93.52% |
Ownership Breakdown
Institutional 82.26%
Insider 0.06%
Public 17.7%
Short Interest
1.19% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in MRK in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-01 | MARALDO DAVID R. | Officer | Conversion of Exercise of derivative security at price 112.16 per share. | 552 | $61,912 |
| 2026-05-01 | SMART DALTON E. III | Officer | Conversion of Exercise of derivative security at price 112.16 per share. | 383 | $42,957 |
| 2026-04-30 | LARSON BETTY D | Officer | 13,435 | — | |
| 2026-04-30 | SMART DALTON E. III | Officer | Conversion of Exercise of derivative security at price 110.03 - 110.95 per share. | 1,408 | $155,349 |
| 2026-04-29 | DELUCA RICHARD ROBERT JR. | Officer | 2,518 | — | |
| 2026-04-29 | ZACHARY JENNIFER L | General Counsel | 2,951 | — | |
| 2026-04-29 | CHATTOPADHYAY SANAT | Officer | 2,597 | — | |
| 2026-04-29 | GUINDO CHIRFI | Officer | Conversion of Exercise of derivative security at price 110.03 per share. | 1,967 | $216,429 |
| 2026-04-29 | DAVIS ROBERT M | Chief Executive Officer | 13,300 | — | |
| 2026-04-29 | WILLIAMS DAVID MICHAEL | Chief Technology Officer | 1,377 | — | |
| 2026-04-29 | LI DEAN Y | Officer | 4,722 | — | |
| 2026-04-29 | LITCHFIELD CAROLINE | Chief Financial Officer | 3,935 | — | |
| 2026-04-29 | OOSTHUIZEN JOHANNES JACOBUS | Officer | 1,377 | — | |
| 2026-02-12 | GUINDO CHIRFI | Officer | Sale at price 121.46 per share. | 10,000 | $1,214,562 |
| 2026-02-10 | LI DEAN Y | Officer | Sale at price 117.52 per share. | 10,235 | $1,202,844 |
| 2026-02-09 | GUINDO CHIRFI | Officer | Sale at price 118.41 per share. | 10,000 | $1,184,101 |
| 2026-02-09 | ZACHARY JENNIFER L | General Counsel | Sale at price 119.15 per share. | 121,573 | $14,485,690 |
| 2026-02-09 | ZACHARY JENNIFER L | General Counsel | Conversion of Exercise of derivative security at price 119.15 per share. | 121,573 | $14,485,690 |
| 2026-02-06 | OOSTHUIZEN JOHANNES JACOBUS | Officer | Sale at price 121.87 per share. | 15,000 | $1,827,992 |
| 2026-02-06 | WILLIAMS DAVID MICHAEL | Chief Technology Officer | Sale at price 121.90 per share. | 5,000 | $609,525 |
| 2026-02-06 | DELUCA RICHARD ROBERT JR. | Officer | Sale at price 120.92 per share. | 37,685 | $4,557,025 |
| 2026-02-06 | WILLIAMS DAVID MICHAEL | Chief Technology Officer | Conversion of Exercise of derivative security at price 77.62 per share. | 5,000 | $388,100 |
| 2026-02-05 | GUINDO CHIRFI | Officer | Sale at price 121.88 per share. | 20,000 | $2,437,676 |
| 2026-02-04 | LITCHFIELD CAROLINE | Chief Financial Officer | Sale at price 119.61 per share. | 41,997 | $5,023,312 |
| 2026-02-04 | SMART DALTON E. III | Officer | Sale at price 119.68 per share. | 6,400 | $765,920 |
MARALDO DAVID R.
Officer
Conversion of Exercise of derivative security at price 112.16 per share.
2026-05-01
552 sh
$61,912
SMART DALTON E. III
Officer
Conversion of Exercise of derivative security at price 112.16 per share.
2026-05-01
383 sh
$42,957
LARSON BETTY D
Officer
2026-04-30
13,435 sh
—
SMART DALTON E. III
Officer
Conversion of Exercise of derivative security at price 110.03 - 110.95 per share.
2026-04-30
1,408 sh
$155,349
DELUCA RICHARD ROBERT JR.
Officer
2026-04-29
2,518 sh
—
ZACHARY JENNIFER L
General Counsel
2026-04-29
2,951 sh
—
CHATTOPADHYAY SANAT
Officer
2026-04-29
2,597 sh
—
GUINDO CHIRFI
Officer
Conversion of Exercise of derivative security at price 110.03 per share.
2026-04-29
1,967 sh
$216,429
DAVIS ROBERT M
Chief Executive Officer
2026-04-29
13,300 sh
—
WILLIAMS DAVID MICHAEL
Chief Technology Officer
2026-04-29
1,377 sh
—
LI DEAN Y
Officer
2026-04-29
4,722 sh
—
LITCHFIELD CAROLINE
Chief Financial Officer
2026-04-29
3,935 sh
—
OOSTHUIZEN JOHANNES JACOBUS
Officer
2026-04-29
1,377 sh
—
GUINDO CHIRFI
Officer
Sale at price 121.46 per share.
2026-02-12
10,000 sh
$1,214,562
LI DEAN Y
Officer
Sale at price 117.52 per share.
2026-02-10
10,235 sh
$1,202,844
GUINDO CHIRFI
Officer
Sale at price 118.41 per share.
2026-02-09
10,000 sh
$1,184,101
ZACHARY JENNIFER L
General Counsel
Sale at price 119.15 per share.
2026-02-09
121,573 sh
$14,485,690
ZACHARY JENNIFER L
General Counsel
Conversion of Exercise of derivative security at price 119.15 per share.
2026-02-09
121,573 sh
$14,485,690
OOSTHUIZEN JOHANNES JACOBUS
Officer
Sale at price 121.87 per share.
2026-02-06
15,000 sh
$1,827,992
WILLIAMS DAVID MICHAEL
Chief Technology Officer
Sale at price 121.90 per share.
2026-02-06
5,000 sh
$609,525
DELUCA RICHARD ROBERT JR.
Officer
Sale at price 120.92 per share.
2026-02-06
37,685 sh
$4,557,025
WILLIAMS DAVID MICHAEL
Chief Technology Officer
Conversion of Exercise of derivative security at price 77.62 per share.
2026-02-06
5,000 sh
$388,100
GUINDO CHIRFI
Officer
Sale at price 121.88 per share.
2026-02-05
20,000 sh
$2,437,676
LITCHFIELD CAROLINE
Chief Financial Officer
Sale at price 119.61 per share.
2026-02-04
41,997 sh
$5,023,312
SMART DALTON E. III
Officer
Sale at price 119.68 per share.
2026-02-04
6,400 sh
$765,920